ProMIS Neurosciences Appoints New CFO

- March 22nd, 2017

Daniel E. Geffken has been selected to be the new Chief Financial Officer at ProMIS Neurosciences (TSX:PMN) a company working on treating neurodegenerative diseases.

Daniel E. Geffken has been selected to be the new Chief Financial Officer at ProMIS Neurosciences (TSX:PMN) a company working on treating neurodegenerative diseases.
As quoted in the press release:

“We are pleased to welcome Daniel Geffken as his broad skill set and experience will contribute significant value to the ProMIS team,” said Eugene Williams,  ProMIS Executive Chairman. “In particular, Daniel’s well–recognized expertise in building science-based companies and track record in strategic fundraising are key capabilities that fit perfectly with the developing needs of ProMIS.”
Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC and brings more than 25 years of experience in the life science industry to his work with ProMIS.
“I am delighted to join ProMIS, a rapidly developing company at the forefront of precision medicine treatments for neurodegenerative diseases, particularly Alzheimer’s disease and ALS,” said Geffken. “I look forward to working with the executive team to assist the company in achieving these important objectives.”
About Daniel Geffken
Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC, a consulting firm providing finance, operations and strategic support to life science companies.  He brings more than 25 years of experience in the life science industry to his work with ProMIS, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He previously served as COO or CFO of four publicly traded and four privately held life science companies, in addition to his consulting clients. Daniel has been chief financial officer of Homology, Inc, GenePeeks, Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc.  He has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a B.S. from The Wharton School, University of Pennsylvania, and M.B.A. from Harvard Business School.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.
ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.

Click here to read the full press release.

Leave a Reply